Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/58027
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2020-06-17T09:38:39Z-
dc.date.available2020-06-17T09:38:39Z-
dc.date.issued2012-
dc.identifier.citationDebono M. (2012). Haloperidol for agitation in persons with dementia (Bachelor's dissertation).en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/58027-
dc.descriptionB.SC.(HONS)NURSINGen_GB
dc.description.abstractHaloperidol for Agitation in Persons with Dementia Agitation and other behavioural symptoms occur in up to 92% of persons with Dementia. Haloperidol, a typical antipsychotic, has been used for many years to control agitation in persons with dementia but its efficacy and safety remains unclear. Thus, the research question of this study: "Is Haloperidol effective in reducing agitation in persons with dementia residing in long term care?'' The Population is agitated elderly patients with dementia, the intervention is Haloperidol in agitated residents with dementia, the comparison is to give Haloperidol vs Placebo, and the outcome is to reduce agitation. The studies reviewed included double blind studies related to the drug Haloperidol and other antipsychotics in the management of behavioural psychological symptoms of dementia including agitation, that were published between the year 1990 and 2012. Moreover, studies related to physical restrain; studies focusing only on the effectiveness of other antipsychotics which are not Haloperidol; and non-English Language studies were excluded. One SR and five RCTs were used for the conduction of this review. CASP tools were the main methods used to appraise the articles. According to the studies reviewed, Haloperidol varies in its effectiveness according to dose studied. An increase in extrapyramidal side effects was noted in persons taking Haloperidol when compared to a placebo. Administering Haloperidol in moderate doses is effective in reducing agitation at the cost of extrapyramidal side effects. As a result Haloperidol needs to be used for no longer than 12 weeks whilst the dose prescribed should be individualised and carefully monitored. Nurses and physicians need to be more aware of its side effects by attending further training. Further research about person-centred non-pharmacological interventions that control agitation in dementia are urgently needed. Keywords: HALOPERIDOL, AGITATION, BEHAVIOURAL SYMPTOMS, ELDERLY PERSONS, EXTRAPYRAMIDAL SYMPTOMS, DEMENTIA B.Sc (Hons.) Nursing April 2012en_GB
dc.language.isoenen_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectAgitation (Psychology)en_GB
dc.subjectDementiaen_GB
dc.subjectAntipsychotic drugsen_GB
dc.subjectLong-term care of the sicken_GB
dc.subjectExtrapyramidal tractsen_GB
dc.subjectNursesen_GB
dc.subjectOlder peopleen_GB
dc.titleHaloperidol for agitation in persons with dementia.en_GB
dc.typebachelorThesisen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.publisher.institutionUniversity of Maltaen_GB
dc.publisher.departmentFaculty of Health Sciences. Department of Nursingen_GB
dc.contributor.supervisorScerri, Anthony-
dc.description.reviewedN/Aen_GB
dc.contributor.creatorDebono, Michael-
Appears in Collections:Dissertations - FacHSc - 2012
Dissertations - FacHScNur - 2012

Files in This Item:
File Description SizeFormat 
Debono_Michael_HALOPERIDOL FOR AGITATION IN PERSONS WITH DEMENTIA.PDF
  Restricted Access
5.78 MBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.